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Nifedipine (NIF) is a poorly water-soluble and a high photosensitive drug, which is among most efficient
drugs for treating diseases such as hypertension and angina pectoris. The main purpose of this work was the
preparation and study of the inclusion complex between NIF and ethylenediamine--cyclodextrin
(NIF/EDA-CD). The NIF/EDA-CD complex has been prepared using the co-precipitation method and charac-
terized by UV-Vis spectroscopy, dynamic light scattering (DLS), differential scanning calorimetry (DSC),
thermogravimetric (TGA), and Fourier-transform infrared (FT-IR) spectroscopy in both solution and solid
state. The 1 : 1 molar stoichiometry is confirmed by the continuous-variation Job’s plot and phase solubility
diagram. The phase solubility diagram showed a complexation constant of 1019.62 M
-1
. In addition, supple-
mentary data from solubility tests have demonstrated that the solubility of NIF in water greatly increased
through complexation with EDA-CD, which is a result of the water-soluble EDA-CD host.
Keywords: ethylenediamine–cyclodextrin; nifedipine; nanocarrier; solubility; drug delivery.
INTRODUCTION
Nifedipine (NIF) with IUPAC name of dimethyl-1,4-di-
hydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine dicarbo-
xylate) (Fig. 1) is a 1,4-dihydropyridine derivative. This drug
is a calcium ion-influx inhibitor that prevents the trans-mem-
brane entry of calcium ions into cardiac and smooth muscles,
which has been widely used for treating hypertension and an-
gina pectoris. It has been reported that NIF is the best among
the most extensively used oral drugs, because it is capable of
decreasing the blood pressure in 15 min. NIF is highly pho-
tosensitive and readily oxidizes to the corresponding nitro-
and nitrosopyridine derivatives with pharmacologically inac-
tive properties [1, 2]. Also, due to its low solubility in water,
NIF cannot perform its best turnover, consequently its effi-
ciency and bioavailability are decreased [3, 4]. However,
many formulation approaches, including the formation of
salts [5] and amorphous solid dispersions [6], particle size re-
duction (e.g., formation of drug nanocrystals or nanosuspen-
sions) [7], addition of surfactants [8] and prodrugs [9], and
complexation (e.g., with cyclodextrins) [10, 11] have been
used to enhance the solubility and stability of hydrophobic
drugs.
Cyclodextrins (CDs) are nontoxic cyclic oligosaccha-
rides produced from starch by enzymatic conversion. The
most superabundant native CDs belong to three types, -CD,
-CD and -CD, which respectively include six, seven and
eight glucopyranose units per ring and have eighteen, twenty
one, and twenty four hydroxyl groups [12]. These cyclic oli-
gosaccharides have a partly hydrophilic outer boundary and
a lipophilic central cavity. An important characteristic fea-
ture of CDs is their ability to form inclusion complexes with
molecules of various kinds of due to their hydrophobic inte-
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rior and hydrophilic outside [13]. The size of the central cav-
ity plays an important role in forming inclusion complexes;
among the three types, -CDs can best function as hosts for
both polar and nonpolar guests, due to their cavity dimen-
sions [14]. Note also that these compounds have some limita-
tions such as weak solubility in aqueous media and relatively
high toxicity.
Nowadays CD derivatives have elicited increasing inter-
est because of their higher aqueous solubilitycompared to
that of native CDs, thereby potentially enhancing the binding
affinity and selectivity of CD derivatives [15, 16] and de-
creasing their toxicity [17]. Therefore, molecular systems
based on CDs and their derivatives have been broadly stud-
ied as important objects in biochemistry and pharmacy
[18 – 20]. These compounds can be used as stabilizers and
solubilizing and targeting agents; therefore, many research-
ers have tried to synthesize various kinds of CD derivatives
to investigate their advantages to the native ones.
In recent years, inclusion complexes between -CD [21]
and some of its derivatives such as 2-hydroxypropyl--CD
(HP--CD) [22, 23], heptakis(2,6-O-dimethyl)--CD
(DM--CD) [24, 25], sulfobutyl ether–alkyl ether CDs [26]
and -CD or other carriers like chitosan, chitosan glutamate
[27], and mannitol [28] with NIF have been reported. The re-
sults of this research showed that these CD derivatives have
greater stability constants and stronger ability of increasing
the solubility of NIF as compared to -CDs. On the other
hand, it is well known that CD conjugates with amino com-
pounds have remarkable ability of the formation of inclusion
complexes with various guest molecules [29 – 33]. These
cationic CDs have widespread potential applications in the
biomedical and pharmaceutical fields [33 – 35]. Among
cationic CDs, EDA--CDs are the novel CD derivatives pre-
senting cationic EDA chains on the CD with the aim of in-
creasing the cavity height and so increasing the potential of
better interaction with guest molecules [11, 32].
Based on these results, an amino derivative of -CD
(EDA-CD) was synthesized in order to make possible syner-
gistic effects, i.e., improvement in (i) aqueous solubility and
(ii) stability of NIF through complexing with EDA-CD. For
this study, we have prepared the inclusion complexes by a
simple co-precipitation method. Studies of the behavior of
inclusion complexes and their characterization were per-
formed by using the phase solubility technique, FT-IR,
UV-Vis spectroscopy, DSC, TGA and Job’s methods. Since
the mechanisms of action of the cationic and anionic groups
in drug delivery systems are different, our primary aim was
restricted to studying the cationic group. For this reason, this
work also evaluated the role of amino groups in aqueous sol-
ubility and stability of NIF in comparison to HP--CD and
DM--CD, in which these groups are neither cationic nor an-
ionic.
EXPERIMENTAL
Materials and Methods
The initial -CD (98%, Merck) was dried under vacuum
at 100°C for 24 h and stored in a desiccator before use.
Ethylenediamine (EDA, 99%, Merck), iodine (I
2
, 99.8%,
Sigma-Aldrich), triphenylphosphine (PPh
3
, 99%, Aldrich),
and NIF (Sigma-Aldrich) were used as received (since NIF
can be degraded by light, special care was taken to protect
the drug throughout formulation and analysis). N,N-Dime-
thylformamide (DMF, 99.8%, Merck, Scharlau) was dried
over calcium hydride, distilled in high vacuum, and stored
over 4 Å molecular sieves. Acetone (99.8%, Merck) and
methanol (MeOH, 99.8%, Merck) were used as received.
Ultrapure water was used in all synthesis. Infrared (IR) spec-
tra were recorded on a Bruker Tensor 27 FT-IR spectrophoto-
meter. The samples were preliminarily ground and mixed
completely with KBr as an IR-transparent matrix, after
which KBr disks were prepared by compressing the powder.
The scans were performed from 4000 to 400 cm
-1
at a resolu-
tion of 8 cm
-1
. All
1
H NMR spectra were recorded on a
Bruker Avance 400 spectrometer at room temperature.
Deuterated solvent, dimethylsulfoxide (DMSO-d
6
), for these
analyses was used as received. The data are reported as
chemical shifts (, ppm) with DMSO-d
6
(2.5 ppm) used as
the internal reference.
Synthesis of CD Derivatives
Heptakis-6-iodo-b-CD. This derivative of -CD was
synthesized using a previously reported method [36]. The fi-
nal pure compound appeared as a white solid; yield, 82%;
m.p., 222°C (decomp.); TLC, one spot at R
f
= 0.1
(BuOH–EtOH–H
2
O, 5 : 4 : 3);
1
H NMR (400MHz,
DMSO-d
6
; , ppm): 6.07 (2-OH), 5.96 (3-OH), 4.98 (H-1),
3.80 (H-6
b
), 3.64 – 3.58 (H-3, 5), 3.42 – 3.28 (H-2, 4, 6
a
).
Heptakis [6-(2-aminoethylamino)-6-deoxy]-b-CD
(EDA-CD). Reaction condition for the preparation of
per-EDA derivative of -CD is similar to that described pre-
viously [11]. In brief, per-iodo-CD (0.3 g, 0.157 mmol) was
dissolved in excess amount of dry EDA (29.95 mmol, 2 mL).
The reaction mixture was heated up to 80°C and stirred for
8 h under inert atmosphere. Then, the attained solution was
cooled at room temperature and the solvent was evaporated
under efficient vacuum. The obtained mixture was poured in
a minimum amount of water to be dissolved and, in order to
get precipitation, poured in acetone. To remove the unreacted
EDA, the mixture was dissolved in water–MeOH (1 : 3) and
precipitated in acetone. Finally, the resulting precipitate was
dried in vacuum desiccator. The final pure compound ap-
peared as a pale-yellow solid; yield, 85%; TLC, no spots;
FT-IR (KBr, thin film; , cm
-1
): 3437 (str. OH and NH), 2925
and 2856 (str. CH), 1634 (str. C-C), 1702 (bend. -NH
2
),
1153 – 1041 (str. C-O);
1
H NMR (400 MHz, DMSO-d
6
; ,
ppm): 5.9 – 5.84 (2,3-OH), 4.89 (H-1), 3.62 – 3.33 (H-2-6),
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2.81 – 2.66 (-NCH
2
CH
2
N-), 1.92 – 1.84 (m, -NH-),
1.22 – 0.97 (-NH
2
); UV-Vis (water; 
max
, nm): 228, 328.
Phase Solubility Studies
Phase solubility studies were carried out in water at room
temperature according to the method described by Higuchi
and Connors [4, 37, 38]. An excess amount of NIF was
mixed with aqueous solutions containing increasing amounts
of EDA-CD (0–7.5 mM). The suspensions were shaken at
room temperature for 72 h. After equilibrium was reached,
the solutions were filtered. An aliquot portion of the filtrate
was diluted appropriately and the concentration of NIF in so-
lution was determined spectrophotometrically on a UV-Vis
spectrophotometer at 245 nm. The solubility of NIF in
EDA-CD solution was calculated and the phase solubility di-
agram was plotted as the solubility of NIF versus concentra-
tion of EDA-CD. All experiments were performed in tripli-
cate.
The stability constant (K
s
) was calculated from the phase
solubility diagram according to the following equation:
K
slope
G m slope
m1
0
:
( )


(1)
where slope is the value found by linear regression, G
0
is the
solubility of NIF in the absence of CDs in water, and m = 1
with the assumption of 1 : 1 stoichiometry.
Stoichiometry of NIF/EDA-CD Inclusion Complex
The stoichiometry of the complex was determined by
Job’s method, according to which it was calculated as the
number of NIF and EDA-CD molecules contained in the
complex [39 – 43]. The Job’s experiments used solutions
with equimolecular 5  10
-5
mol L
-1
concentrations of NIF
[N] and EDA-CD [E] components, prepared by mixing their
various volumes (1 mL : 9 mL; 2 mL : 8 ml; 3 mL : 7 mL,
and so on), so that the total concentration [E] + [N] remained
constant. After stirring, the absorbance at 
max
was measured
for all solutions and the difference in absorbance of NIF in
the presence and absence of EDA-CD, A (A = A
0
–A), in
the presence (A) and absence (A
0
) of CD was plotted against
R (R = [NIF] : ([NIF] + [EDA-CD])) [44]. An equimolar
aqueous solution of each EDA-CD concentration was used
as the blank. The Job’s plot was constructed using the
UV-Vis spectrophotometric data, according to the shift of

max
around 245 nm. Each complex solution was measured
in triplicate.
Preparation of NIF/EDA-CD Inclusion Complex
The drug-incorporated carriers were prepared according
to the co-precipitation method.
First, NIF was dissolved in MeOH as water-miscible sol-
vent. Then, the resulting solution was poured quietly into the
aqueous carrier solutions (under vigorous agitation at room
temperature) with NIF : -CD and NIF : EDA-CD molar ra-
tios 1 : 1. The mixture was stirred at room temperature for
two days and then the solvent was slowly evaporated. The in-
clusion complex (precipitated as a powder) was pulverized
and kept in a desiccator until no solvent was retained. In or-
der to remove free drug, the solution was purified by filtra-
tion and then drug-incorporated carriers were washed with
MeOH for several times.
Characterization of Inclusion Complex
UV-Vis spectroscopy. Complex formation between NIF
and hosts was studied by the spectral shift method. UV-Vis
spectra of aqueous solutions of -CD, EDA-CD, NIF/-CD
and NIF/EDA-CD (2.5  10
-2
mmol L
-1
) were recorded us-
ing Cary 50 (Varian, Australia) UV-Vis dual-beam
spectrophotometer in quartz cuvettes with 1 cm path length.
Other UV-Vis analyses were performed on the same
spectrophotometer.
FT-IR spectroscopy. This spectral analysis was similar
to that reported in the Materials and Methods section.
DLS measurements. The particle size and distribution
of complexes were measured by dynamic light scattering
(DLS) method in aqueous solutions of NIF/EDA-CD com-
plex at a constant temperature (25  0.1°C) using a Malvern
Nano-ZS scattering apparatus (ZEN 3600, Malvern Instru-
ments Ltd., UK). The DLS instrument used a 633 nm red la-
ser and analyzed the light scattered at an angle of 90° by a
non-invasive backscatter technique for samples appropriately
diluted in distilled water. All samples were analyzed using
the DLS Software (Version 5.02) from Malvern Instruments.
Thermal analysis. The thermal properties of NIF,
EDA-CD and NIF/EDA-CD complex were studied using
DSC and TGA measurements on 409 PG instrument
(NETZSCH, Germany). A sample weighing 3 – 10 mg was
put in crimped aluminium pan and heated from room temper-
ature to 350°C at a constant rate of 10 K/min under dynamic
nitrogen atmosphere. An empty pan sealed in the same man-
ner was used as the reference.
Solubility studies. Solubility of -CD, EDA-CD and
their complexes with NIF in water was determined. In brief,
excess amounts of samples were added to 2 mL of water to
ensure the solution reaching saturation. The suspensions
were kept with stirring at 25, 35, 45 and 60°C for 24 h. After
attaining equilibrium, the samples were filtered via sintered
glass funnels (Pyrex) and centrifuged to remove the insolu-
ble substances. The filtrated sample was dried until constant
weight being reached. The solubility of samples in water
could be calculated from the difference between the initial
and residual amounts.
RESULTS AND DISCUSSION
Synthesis and Characterization of -CD Derivatives
Native CDs exhibit several limitations in terms of size,
shape, aqueous solubility, and toxicity. To overcome these
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limitations and to have prefect tools for complexing with a
wide circle of molecules, modification of CDs has become
an attractive research field. One of the most common meth-
ods applied to attach a substituent on the -CD core and
branches is via activation of the primary hydroxyl groups of
-CD by treatment with electrophilic reagents. In this re-
spect, heptaiodo-CD is an important precursor for obtaining
a wide variety of modified CDs. Nucleophiles can attack the
electrophilic carbon (C-6) to yield the corresponding hepta-
functionalized derivatives. In this study, the electrophilic pre-
cursor treated with the corresponding alkyldiamine was used
to obtain the required amino -CD derivative through a nuc-
leophilic substitution reaction in a good yield. As is shown in
Scheme 1, a symmetric iodo derivative was first prepared by
selective replacement of seven primary hydroxyls in the
presence of secondary hydroxyls by a nucleophilic reaction
[36]. The purified iodo derivative was then converted to
EDA derivative through replacement of iodo groups with ex-
cess EDA groups as both nucleophile and solvent at 70°C
[11].
FT-IR and
1
H NMR spectral analyses were similar to
those reported in the corresponding literature [11, 36]. The
total conversion of CD to iodo-CD and EDA-CD was con-
firmed by disappearance of the primary hydroxyl proton
signal at 4.5 ppm and the appearance of the single anomeric
proton signal at 4.8 ppm in the
1
H NMR spectrum. At the
same time, new peaks analogous to those of the aliphatic pro-
tons of EDA have appeared. These observations confirmed
that pure EDA-CD was synthesized.
Phase Solubility Studies
Constructing phase-solubility diagram is a widely ac-
cepted method for studying drug/CD complexes because it
provides information on both the solubilizing ability of CDs
and the stability constants of inclusion complexes [37]. Fig-
ure 2 demonstrates a linear relationship between the amount
of solubilized NIF and the EDA-CD concentration in solu-
tion. This relationship was classified as typical A
L
type,
where “A” type curve indicates the formation of soluble
complex and “A
L
” indicates a linear increase in solubility.
The slope below unity can be indicative of an inclusion com-
plex with the molar ratio 1 : 1 between NIF and EDA-CD
molecules [37, 45].
The stability constant (K
s
) for NIF/EDA-CD complex
was calculated from the solubility data and found to be
1019.62 M
-1
. The previously reported K
s
values for NIF in
the presence of native -CDs and -CD derivatives are given
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Scheme 1. Synthesis of EDA-CD.
Fig. 2. Phase-solubility diagram of NIF in aqueous solutions of
EDA-CD.
TABLE 1. Stability Constants of NIF in the Presence of Native
-CD and -CD Derivatives
Compound
Type
of diagram
Stability constants (M
-1
)
References
K1:1 K1:2
EDA-CD AL 1019.62 - -
-CD AL 139.23 - [45]
HP--CD AL 97 - [24]
60 - [22]
DM--CD AP 216 43 [24]
in Table 1. These data for K
s
values showed that EDA-CD
has greater stability constants and stronger ability of increas-
ing the solubility for NIF as compared to those for -CD,
HP--CD, and DM--CD, and suggested that this improve-
ment in solubility is definitely related to the structure of
EDA-CD derivative.
As reported in literature, the most suitable K
s
values for
improvement of the solubility and stability of poorly soluble
drugs were considered between 50 and 5000 M
-1
[1, 46]. Re-
sults suggest that the inclusion complexes have been formed,
and it follows from the calculated K
s
values that these inclu-
sion complexes are comparatively stable.
Stoichiometry of the NIF/EDA-CD Inclusion Complex
Stoichiometric ratio is an important parameter for esti-
mating characteristics of the CD-based inclusion complexes.
One of the best methods for determination of the stoichio-
metry of inclusion complexes is Job’s method [47]. The Job’s
plot was constructed using UV-Vis spectrophotometry data
according to the continuous variation method. The concen-
tration of complexes in a series of samples with continuously
variable molar fraction of components can be measured, and
the maximum absorbance of complex will be observed in the
sample where the molar ratio R of components corresponds
to the stoichiometric complexation. The maximum amount
of the NIF complex was observed for R = 0.5, which indi-
cated that the main stoichiometry was 1 : 1 (Fig. 3). In addi-
tion, this stoichiometry ratio is confirmed by phase solubility
data (see below). The 1 : 1 stoichiometry ratio between NIF
and -CD was also shown by results of C. Yáñez et al. (see
[48]).
Characterization of Inclusion Complex
The interaction between NIF guest and -CD host has
been previously studied and it was suggested that the inclu-
sion moiety was the nitroaromatic group, this interaction be-
ing revealed by the differential pulse polarography [48].
Here, the interaction of NIF and EDA-CD has been studied
using UV-Vis and FT-IR spectroscopy and evaluated by com-
paring the spectral shifts, which suggested that the inclusion
moiety is the nitroaromatic ring.
UV-Vis spectral analysis. UV-Vis spectroscopy is an
important tool in the study of complexation. Figure 4 shows
the absorption spectra of NIF, EDA-CD and NIF/EDA-CD
complex. The results showed that the absorption spectrum of
NIF was almost similar to that of NIF/EDA-CD inclusion
complex; however, the absorbance intensity of the inclusion
complex is lower than that of NIF at some wavelengths. It
can be seen that 
max
of NIF has no shift in the presence of
EDA-CD. Obviously, it is fundamental that the spectrophoto-
metric method is developed for determination of NIF
nitroaromatic moiety based on the measurements of changes
in the absorbance at 
max
= 245 nm. The absorbance of
NIF/EDA-CD inclusion complex compared to NIF
absorbance at 245 nm in the same concentration has lower
intensity. Clearly, a decrease in the peak intensity is due to
the formation of complex via the reducible nitroaromatic
ring of NIF. All these results suggest that EDA-CD can form
an inclusion complex with nitroaromatic moiety of NIF.
FT-IR analysis. The presence of a guest molecule (NIF)
in the EDA-CD cavity was confirmed by changes in the
FT-IR spectra caused by a physical interaction between the
drug and host. Figure 5 shows the FT-IR spectra of NIF,
EDA-CD and NIF/EDA-CD complex. The NIF spectrum
shows noticeable peaks at 3333, 3101, 2929, 1687, 1622,
1531, 1380, and 1121 cm
-1
, which are analogous to aromatic
N-H stretching, C-H aromatic stretching, C-H aliphatic
stretching, C=O stretching in ester, and C=C stretching in ar-
omatic, -NO
2
, -C-CH
3
and -C-O-ester groups. The prominent
peaks of EDA-CD are observed at 3382, 2925, and
1041 cm
-1
, corresponding to O-H, N-H, NH
2
stretching, C-H
stretching, and C-O-C asymmetric stretching, respectively.
The NIF/EDA-CD complex spectrum shows that the NO
2
stretching band of NIF has disappeared. Furthermore, the ab-
sorption band at 1687 cm
-1
(attributed to stretching vibration
of the ester carbonyl of NIF) shifted to a lower frequency
(1653 cm
-1
) upon complexation with EDA-CD, where this
might be ascribed to intermolecular hydrogen bonding be-
tween NIF and EDA-CD. Based on these results, inclusion
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Fig. 3. Job’s plot of NIF/EDA-CD complex. Fig. 4. UV-Vis absorption spectra of NIF, EDA-CD and
NIF/EDA-CD inclusion complex.
complex formation is successfully achieved and NIF is in-
serted through the nitroaromatic ring.
DLS analysis. For additional characterization, particle
sizes of NIF/EDA-CD complex in aqueous solution were
studied by DLS. Figure 6 shows the plots of particle size sta-
tistics in terms of their number and volume distribution.
These measurements show the presence of nanodrug in aque-
ous solution.
Thermal analysis. The thermal properties of NIF,
EDA-CD and NIF/EDA-CD complex were studied by DSC
and TGA. The DSC curve of NIF (Fig. 7a) shows it to be an
anhydrous crystalline compound, with visible intense and
clearly defined endothermic peak at 178.6°C corresponding
to the melting temperature. The DSC curve of EDA-CD
presents a broader endothermic peak that can be attributed to
the loss of water at 66 – 100°C; another endothermic peak
appeared at 310°C for the decomposition. The DSC curve of
the NIF/EDA-CD complex indicates effective disappearance
of the endothermic peaks around 60°C (corresponding to the
water loss) and about 178.6 °C (corresponding to the NIF
melting). The disappearance of endothermic peaks corre-
sponding to the drug melting and water loss can be attributed
to the inclusion of NIF in the CD cavity. In addition, dis-
placement of the NIF melting peak to lower temperatures
(~171.1°C) can be seen. This displacement can be explained
by the interaction between EDA-CD and NIF during the
heating involved in the DSC process. DSC also provides
evaluation of the purity of complexes.
TGA is a complementary technique that can show the
composition and changes in thermal stability of the samples.
The successful formation of NIF inclusion complex with
EDA-CD and its thermal stability is also reflected by the
TGA curves (Fig. 7b). The TGA curve shape of EDA-CD
was almost similar to that of NIF/EDA-CD inclusion com-
plex, but it showed a higher slope attributed to the loss of wa-
ter. At the same time, the DSC curve of NIF/EDA-CD indi-
cates a lower slope of the peak in comparison to that for
EDA-CD. This result is indicative of the replacement of wa-
ter with NIF and the formation of inclusion complex between
NIF and EDA-CD. As can be seen in Fig. 7b, a weight loss is
observed after approximately 230°C, and the TGA curve of
NIF shows a mass loss at 235°C. Comparison of the TGA
curves shows that NIF/EDA-CD exhibits mass loss with
higher slope than EDA-CD (31.90% vs. 20.75%, respec-
tively). In comparing the curves of NIF/EDA-CD and NIF, it
can be found that the slope of weight loss for NIF is signifi-
cantly greater than that for NIF/EDA-CD (73.85% vs.
31.90%, respectively). These results indicate formation of
the inclusion complex between NIF and EDA-CD.
Solubility studies. In general, native CDs have low solu-
bility in water, and the solubility of -CD is lower than that
of á,-CDs. This behavior is related to the special structure of
-CD that causes interaction with water, which lowers the
enthalpy and causes inappropriate entropy. In addition, the
solubility of CDs in water will decrease on forming inclusion
complexes. The solubility of CDs strongly depends on the
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Fig. 5. FT-IR spectra of NIF, EDA-CD and NIF/EDA-CD complex.
Fig. 6. Size statistics of NIF/EDA-CD complex particles in terms of
number and volume distributions in aqueous solution as determined
by DLS.
temperature and the type of functional groups in CD deriva-
tives [49].
The solubility data for -CD, EDA-CD, NIF, and NIF in
the presence of native -CDs, EDA-CD and other -CD de-
rivatives (from previous reports) are summarized in Table 2.
These data are indicative of the existence of highly wa-
ter-soluble NIF/EDA-CD complexes in solution. This phe-
nomenon is also true for the obtained complex of EDA-CD
with NIF. In addition, it is clearly seen from Table 2 that the
solubilities of all samples in water increase with the tempera-
ture. From Table 2, it can be understood that the solubility of
NIF/EDA-CD is much higher than the solubility of native
NIF and NIF/HP--CD and slightly lower than the solubility
of NIF/DM--CD. From these data, it can be concluded that
the solubility of NIF increases because of the formation of
inclusion complexes between NIF and EDA-CD or other de-
rivatives.
In Table 2, EDA-CD is among cationic groups and has
been compared only to neutral compounds. Since the com-
pounds with anionic group are different from those of com-
pounds with cationic group, such a comparison is not consid-
ered in this table.
CONCLUSION
This study demonstrated that the inclusion complex be-
tween NIF and EDA-CD could be prepared successfully.
Complexation was systematically analyzed using phase solu-
bility studies, Job’s method, UV-Vis and FT-IR spectra, and
DSC and TGA techniques. Phase solubility studies and Job’s
method indicated that CDs could form stable 1 : 1 inclusion
complexes with NIF in solution. The stability constant of this
inclusion complex was found to be K
s
= 1019.62 M
-1
, which
was greater than the values for inclusion complexes between
NIF and -CD, HP--CD and DM--CD. In addition,
UV-Vis and FT-IR spectroscopy showed that nitroaromatic
moiety of NIF was encapsulated inside the EDA-CD cavity.
Furthermore, the comparison of water solubilities between
-CD, HP--CD and EDA-CD indicated that EDA groups on
-CD led to significant increase in its solubility. It is con-
cluded that water solubility and stability of NIF are remark-
ably increased by its complexation with cationic EDA-CD in
comparison to neutral CDs such as native -CD, HP--CD
and DM--CD.
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Fig. 7. DSC (a) and TGA (b) curves of NIF, EDA-CD and NIF/EDA-CD complex.
TABLE 2. Solubility Data for -CD, EDA-CD, NIF, and NIF in the
Presence of Native -CDs and -CD Derivatives
Sample
Temperature, °C
References
25 35 45 60
NIF 0.51 0.9 1.3 3.4 –
-CD 1.61
a
2.51 4.44 8.53 –
EDA-CD 5.83 7.00 14.01 46.66 –
NIF/-CD
complex
0.96 1.49 2.80 5.42 –
NIF/EDA-CD
complex
1.9 2.28 4.56 13.87 –
NIF/DM--CD
complex
2.77 – – – [25]
NIF/HP--CD
complex
0.8
b
– – – [23]
a
g/100 mL
b
30°C
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